Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 [Yahoo! Finance]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]
Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting [Yahoo! Finance]